Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiometabolic risk and chronobiology in autonomous adrenal cortisol secretion
2022-000161-40Phase 4Active
- Sponsor
- Medical University of Vienna
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of metyrapone in Mild hypercortisolism (SCS), Adrenal adenoma and Hypothalamic-pituitary-adrenal axis disorder, sponsored by Medical University of Vienna. Primary endpoint: Hepatic lipid content. Started Jun 2022; status: active.
02
Drugs
metyrapone
03
Conditions
Mild hypercortisolism (SCS)Adrenal adenomaHypothalamic-pituitary-adrenal axis disorder
Beyond the preview
Go deeper on 2022-000161-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000161-40.